My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

38.75 +4.26 (+12.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,409,425
Open 34.79
Bid (Size) 38.75 (1)
Ask (Size) 39.00 (1)
Prev. Close 34.49
Today's Range 34.61 - 39.08
52wk Range 6.760 - 46.98
Shares Outstanding 94,873,407
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA... 
Via Benzinga
Topics Stocks
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection
FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germany as the launch market. 
Via Benzinga

Performance

YTD
-12.3%
-12.3%
1 Month
+12.4%
+12.4%
3 Month
+8.2%
+8.2%
6 Month
+18.0%
+18.0%
1 Year
+348.0%
+348.0%

More News

Read More
Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues
Via Stocktwits
Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug
Via Investor's Business Daily
Earnings Scheduled For August 6, 2025
Via Benzinga
Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility
From Scholar Rock
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday?
Via Chartmill
Why Scholar Rock Stock Bounced Higher on Monday
Via The Motley Fool
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
How Do Investors Really Feel About Scholar Rock Holding?
Via Benzinga
Here's How Much $1000 Invested In Scholar Rock Holding 5 Years Ago Would Be Worth Today
Via Benzinga
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment
From Scholar Rock
Via Business Wire
Here's How Much You Would Have Made Owning Scholar Rock Holding Stock In The Last 5 Years
Via Benzinga
Why Scholar Rock Stock Wilted on Wednesday
Via The Motley Fool
Scholar Rock (SRRK) Q2 Loss Widens 63%
Via The Motley Fool
Scholar Rock Holding Corp (NASDAQ:SRRK) Reports Q2 2025 Wider Loss but Market Shows Optimism Ahead of Key FDA Decision
Via Chartmill
Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
Director Sells 11,136 Shares of SRRK, a Stock Up 330% in Past Year
Via The Motley Fool
Topics Regulatory Compliance
Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial
From Scholar Rock
Via Business Wire

Frequently Asked Questions

Is Scholar Rock Holding Corporation - Common Stock publicly traded?
Yes, Scholar Rock Holding Corporation - Common Stock is publicly traded.
What exchange does Scholar Rock Holding Corporation - Common Stock trade on?
Scholar Rock Holding Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Scholar Rock Holding Corporation - Common Stock?
The ticker symbol for Scholar Rock Holding Corporation - Common Stock is SRRK on the Nasdaq Stock Market
What is the current price of Scholar Rock Holding Corporation - Common Stock?
The current price of Scholar Rock Holding Corporation - Common Stock is 38.75
When was Scholar Rock Holding Corporation - Common Stock last traded?
The last trade of Scholar Rock Holding Corporation - Common Stock was at 09/26/25 04:00 PM ET
What is the market capitalization of Scholar Rock Holding Corporation - Common Stock?
The market capitalization of Scholar Rock Holding Corporation - Common Stock is 3.68B
How many shares of Scholar Rock Holding Corporation - Common Stock are outstanding?
Scholar Rock Holding Corporation - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.